These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 38773569)

  • 1. Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease.
    Penny LK; Lofthouse R; Arastoo M; Porter A; Palliyil S; Harrington CR; Wischik CM
    Transl Neurodegener; 2024 May; 13(1):25. PubMed ID: 38773569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.
    Ossenkoppele R; van der Kant R; Hansson O
    Lancet Neurol; 2022 Aug; 21(8):726-734. PubMed ID: 35643092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review.
    Oosthoek M; Vermunt L; de Wilde A; Bongers B; Antwi-Berko D; Scheltens P; van Bokhoven P; Vijverberg EGB; Teunissen CE
    Alzheimers Res Ther; 2024 Apr; 16(1):93. PubMed ID: 38678292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.
    Blennow K; Hampel H; Zetterberg H
    Neuropsychopharmacology; 2014 Jan; 39(1):189-201. PubMed ID: 23799530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Bio-Hermes Study: Biomarker database developed to investigate blood-based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer's disease.
    Mohs RC; Beauregard D; Dwyer J; Gaudioso J; Bork J; MaGee-Rodgers T; Key MN; Kerwin DR; Hughes L; Cordell CB;
    Alzheimers Dement; 2024 Apr; 20(4):2752-2765. PubMed ID: 38415908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force.
    Cummings J; Fox N; Vellas B; Aisen P; Shan G
    J Prev Alzheimers Dis; 2018; 5(2):103-109. PubMed ID: 29616703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings.
    Blennow K; Zetterberg H
    Prog Mol Biol Transl Sci; 2019; 168():3-23. PubMed ID: 31699324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force.
    Cummings J; Blennow K; Johnson K; Keeley M; Bateman RJ; Molinuevo JL; Touchon J; Aisen P; Vellas B
    J Prev Alzheimers Dis; 2019; 6(3):157-163. PubMed ID: 31062825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.
    Passamonti L; Vázquez Rodríguez P; Hong YT; Allinson KS; Williamson D; Borchert RJ; Sami S; Cope TE; Bevan-Jones WR; Jones PS; Arnold R; Surendranathan A; Mak E; Su L; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
    Brain; 2017 Mar; 140(3):781-791. PubMed ID: 28122879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
    Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design.
    Moscoso A; Karikari TK; Grothe MJ; Ashton NJ; Lantero-Rodriguez J; Snellman A; Zetterberg H; Blennow K; Schöll M
    Alzheimers Dement; 2022 Dec; 18(12):2614-2626. PubMed ID: 35226405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
    Koychev I; Hofer M; Friedman N
    J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials.
    Brosch JR; Farlow MR; Risacher SL; Apostolova LG
    Neurotherapeutics; 2017 Jan; 14(1):62-68. PubMed ID: 27873182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.
    Pascoal TA; Mathotaarachchi S; Shin M; Park AY; Mohades S; Benedet AL; Kang MS; Massarweh G; Soucy JP; Gauthier S; Rosa-Neto P;
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):1021-1030. PubMed ID: 29396637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is Cerebrospinal Fluid Superoxide Dismutase 1 a Biomarker of Tau But Not Amyloid-Induced Neurodegeneration in Alzheimer's Disease?
    McLimans KE; Clark BE; Plagman A; Pappas C; Klinedinst B; Anatharam V; Kanthasamy A; Willette AA
    Antioxid Redox Signal; 2019 Sep; 31(8):572-578. PubMed ID: 31088292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology.
    Ashton NJ; Brum WS; Di Molfetta G; Benedet AL; Arslan B; Jonaitis E; Langhough RE; Cody K; Wilson R; Carlsson CM; Vanmechelen E; Montoliu-Gaya L; Lantero-Rodriguez J; Rahmouni N; Tissot C; Stevenson J; Servaes S; Therriault J; Pascoal T; Lleó A; Alcolea D; Fortea J; Rosa-Neto P; Johnson S; Jeromin A; Blennow K; Zetterberg H
    JAMA Neurol; 2024 Mar; 81(3):255-263. PubMed ID: 38252443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
    Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
    J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.